CO2021004534A2 - Proteínas de unión anti-cd38, anti-cd28, and anti-cd3 triespecíficas y métodos de uso para tratar una infección viral - Google Patents

Proteínas de unión anti-cd38, anti-cd28, and anti-cd3 triespecíficas y métodos de uso para tratar una infección viral

Info

Publication number
CO2021004534A2
CO2021004534A2 CONC2021/0004534A CO2021004534A CO2021004534A2 CO 2021004534 A2 CO2021004534 A2 CO 2021004534A2 CO 2021004534 A CO2021004534 A CO 2021004534A CO 2021004534 A2 CO2021004534 A2 CO 2021004534A2
Authority
CO
Colombia
Prior art keywords
viral infection
binding proteins
trispecific
treat
methods
Prior art date
Application number
CONC2021/0004534A
Other languages
English (en)
Spanish (es)
Inventor
Lan Wu
Ling Xu
Edward Seung
Gary Nabel
Zhi-Yong Yang
Tarik Dabdoubi
Béatrice Cameron
Cendrine Lemoine
Catherine Prades
Ronnie Wei
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/055084 external-priority patent/WO2019074973A2/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2021004534A2 publication Critical patent/CO2021004534A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CONC2021/0004534A 2018-10-09 2021-04-12 Proteínas de unión anti-cd38, anti-cd28, and anti-cd3 triespecíficas y métodos de uso para tratar una infección viral CO2021004534A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2018/055084 WO2019074973A2 (en) 2017-10-10 2018-10-09 ANTI-CD38 ANTIBODIES AND METHODS OF USE
US201962831608P 2019-04-09 2019-04-09
US201962831572P 2019-04-09 2019-04-09
EP19306097 2019-09-11
PCT/US2019/055232 WO2020076853A1 (en) 2018-10-09 2019-10-08 Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection

Publications (1)

Publication Number Publication Date
CO2021004534A2 true CO2021004534A2 (es) 2021-04-30

Family

ID=70165121

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0004534A CO2021004534A2 (es) 2018-10-09 2021-04-12 Proteínas de unión anti-cd38, anti-cd28, and anti-cd3 triespecíficas y métodos de uso para tratar una infección viral

Country Status (15)

Country Link
US (2) US11530268B2 (cg-RX-API-DMAC7.html)
EP (1) EP3864043A1 (cg-RX-API-DMAC7.html)
JP (1) JP7462621B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210075129A (cg-RX-API-DMAC7.html)
CN (1) CN113166254A (cg-RX-API-DMAC7.html)
AU (1) AU2019357467A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006558A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115679A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004534A2 (cg-RX-API-DMAC7.html)
IL (1) IL282126A (cg-RX-API-DMAC7.html)
MX (1) MX2021004147A (cg-RX-API-DMAC7.html)
SG (1) SG11202103478RA (cg-RX-API-DMAC7.html)
TW (1) TWI856979B (cg-RX-API-DMAC7.html)
WO (1) WO2020076853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102223B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
AR103488A1 (es) * 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
ES2894304T3 (es) 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
MX2022004881A (es) 2019-10-25 2022-05-16 Sanofi Sa Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas.
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250144193A1 (en) * 2022-02-19 2025-05-08 Salvitus, Inc. Probiotic vaccines and related methods of use
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
CN118667026A (zh) 2023-03-15 2024-09-20 三生国健药业(上海)股份有限公司 抗muc17*cd3*cd28三特异性抗体
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN121586731A (zh) 2023-07-31 2026-02-27 赛诺菲 抗cd38 t细胞接合器在治疗外周t细胞淋巴瘤中的方法和用途
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN121511263A (zh) * 2024-05-27 2026-02-10 杭州阿诺生物医药科技有限公司 一种多功能融合多肽

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN112225798B (zh) 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
CN104080805B (zh) 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
US20140213772A1 (en) 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. BIFUNCTIONAL MOLECULE AND USE OF IT
CN108264557B (zh) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用

Also Published As

Publication number Publication date
KR20210075129A (ko) 2021-06-22
CA3115679A1 (en) 2020-04-16
SG11202103478RA (en) 2021-05-28
JP2022512649A (ja) 2022-02-07
CN113166254A (zh) 2021-07-23
ZA202102223B (en) 2024-07-31
MX2021004147A (es) 2021-09-08
IL282126A (en) 2021-05-31
AU2019357467A1 (en) 2021-05-27
US20200140552A1 (en) 2020-05-07
JP7462621B2 (ja) 2024-04-05
BR112021006558A2 (pt) 2021-07-13
TW202035458A (zh) 2020-10-01
US11530268B2 (en) 2022-12-20
TWI856979B (zh) 2024-10-01
WO2020076853A1 (en) 2020-04-16
US20230357401A1 (en) 2023-11-09
EP3864043A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
AR116718A1 (es) Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica
ZA202102223B (en) Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CO2020000438A2 (es) Anticuerpos anti-ctla-4 y sus usos
SA520420631B1 (ar) الأجسام المضادة لـ cd3 واستخداماتها
PH12020552232A1 (en) IL-11 Antibodies
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
PH12020552229A1 (en) Il-11ra antibodies
CL2019002310A1 (es) Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797)
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
SA519402531B1 (ar) Cea بروتينات ربط متعددة النوعية مُستَهْدفة
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
CR20200467A (es) Agentes anticuerpos anti-cd25
BR112021012631A2 (pt) Anticorpos anti-ctla4 e métodos de uso dos mesmos
IL280512A (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
MX2019014577A (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
CL2018000254A1 (es) Moléculas de unión a pd-1 y métodos de uso de las mismas
CL2018000908A1 (es) Anticuerpos anti-lag3 y su uso para tratar cáncer o infección viral.
MX389710B (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
MX2021007093A (es) Anticuerpos btla.
MY188355A (en) Human antibodies to pd-l1
IL288727A (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof